|
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma
Background:
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as bevacizumab can locate tumor cells and kill them without harming normal cells. It is not yet known if combination chemotherapy is more effective with or without bevacizumab in treating malignant mesothelioma. Randomized phase II trial to compare the effectiveness of combination chemotherapy with or without bevacizumab in treating patients who have malignant mesothelioma.
Inclusion Criteria:
Histologically or cytologically confirmed malignant pleural or peritoneal mesothelioma that is not amenable to curative surgery.
Location/Contact Information:
California
City of Hope Comprehensive Cancer Center, Duarte, California, 91010-3000, United States;
Recruiting
Marianna Koczywas, MD 626-359-8111
mkocywas@coh.org
City of Hope Medical Group, Pasadena, California, 91105, United States; Recruiting
Mark V. McNamara, MD 626-396-2900
mmcnamara@ccsmg.com
University of California Davis Cancer Center, Sacramento, California, 95817, United States;
Recruiting
David R. Gandara, MD 916-734-3772
dgandara@cc.ucdmc.ucdavis.edu
Illinois
Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, 62526, United States;
Recruiting
James L. Wade, MD 217-876-6603
Ingalls Memorial Hospital, Harvey, Illinois, 60426, United States;
Recruiting
Mark F. Kozloff, MD 708-333-2300
LaGrange Memorial Hospital, LaGrange, Illinois, 60525, United States; Recruiting
James E. Hannigan, MD 708-579-3418
Louis A. Weiss Memorial Hospital, Chicago, Illinois, 60640, United States; Recruiting
Gary D. Steinberg, MD 773-564-5272
Loyola University Medical Center, Maywood, Illinois, 60153, United States; Recruiting
Joseph I. Clark, MD 708-327-3236
jclark@lumc.edu
Oncology/Hematology Associates of Central Illinois, P.C., Peoria, Illinois, 61602, United States;
Recruiting
James A. Knost, MD, FACP 309-672-5681
University of Chicago Cancer Research Center, Chicago, Illinois, 60637-1470, United States;
Recruiting
Hedy L. Kindler, MD 773-702-0360
Indiana
CCOP - Northern Indiana CR Consortium, South Bend, Indiana, 46601, United States;
Recruiting
David Allen Taber, MD 800-284-7370
Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, 46885-5099, United States;
Recruiting
David Frank Sciortino, MD 219-484-8830
Michigan
Lakeland Medical Center - St. Joseph, Saint Joseph, Michigan, 49085, United States;
Recruiting
Eric P. Lester, MD 616-982-4963
New York
Memorial Sloan-Kettering Cancer Center, New York, New York, 10021, United States;
Recruiting
Lee M. Krug, MD 212-639-8420
Pennsylvania
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, 19104-4283, United States;
Recruiting
James Stevenson, MD 215-662-8756
Texas
University of Texas - MD Anderson Cancer Center, Houston, Texas, 77030-4009, United States;
Recruiting
Charles Lu, MD 713-792-6363
Study chairs or principal investigators
Hedy L. Kindler, MD, Study Chair
University of Chicago Cancer Research Center
|
 |
| Get a Free Info Pack |
|
|
